Citation Impact
Citing Papers
Sensitization of Human Carcinoma Cells to Alkylating Agents by Small Interfering RNA Suppression of 3-Alkyladenine-DNA Glycosylase
2005 StandoutNobel
Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma
2008
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate
2015 StandoutNobel
Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802
2012
Vitamin D Deficiency and Risk of Cardiovascular Disease
2008 Standout
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
2012
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
2010
IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
2010
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
2009 Standout
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
2010
Hallmarks of Cancer: The Next Generation
2011 Standout
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
Thromboprophylaxis in the Cancer Patient
2001
Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy
2013
The risk of venous thromboembolism is increased throughout the course of malignant glioma
2000
Phase II Pilot Study of Bevacizumab in Combination with Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability
2008
Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis
2012
IDH1andIDH2Mutations in Gliomas
2009 Standout
Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
2017
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
2012
Interactions between the microbiota, immune and nervous systems in health and disease
2017 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
2008
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
Contribution of platelets to tumour metastasis
2011 Standout
Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center
2011
Glioblastoma and Other Malignant Gliomas
2013 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Thromboembolic disease in patients with high-grade glioma
2012
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry
2013
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
2012
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
2013
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis
2005 Standout
Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme
2010
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
Molecularly targeted therapy for malignant glioma
2007
Sex differences in cancer mechanisms
2020
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
2014 Standout
Alkylation damage in DNA and RNA—repair mechanisms and medical significance
2004
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
2008 Standout
3D Slicer as an image computing platform for the Quantitative Imaging Network
2012 Standout
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
2008 Standout
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
2010
Sex differences in trauma and posttraumatic stress disorder: A quantitative review of 25 years of research.
2006 Standout
Parathyroid hormone and the cardiovascular system
2008
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas
2010
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine
2005
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma1
2006
Anaplastic Oligodendroglioma and Oligoastrocytoma
2007
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
2001
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
2013 Standout
MRI perfusion in determining pseudoprogression in patients with glioblastoma
2012
Medical management of patients with brain tumors
2006
Malignant Gliomas in Adults
2008 Standout
Prevention of Venous Thromboembolism
2004 Standout
Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology
2008
PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma
2010
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Prevention of Venous Thromboembolism
2008 Standout
Primary brain tumours in adults
2012 Standout
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Psychiatric and Psychosocial Outcome of Orthotopic Liver Transplantation
2002
Antiangiogenic therapies for high-grade glioma
2009
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Astrocyte–endothelial interactions at the blood–brain barrier
2005 Standout
Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances
2006
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010
Thromboembolism in brain tumors
2001
Diagnosis and Treatment of High-Grade Astrocytoma
2007
Venous thromboembolism and survival in patients with high-grade glioma
2007
A Phase III Clinical Evaluation of Herpes Simplex Virus Type 1 Thymidine Kinase and Ganciclovir Gene Therapy as an Adjuvant to Surgical Resection and Radiation in Adults with Previously Untreated Glioblastoma Multiforme
2000
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Assessing Risk of Venous Thromboembolism in the Patient With Cancer
2009
Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma
2007
Modulation of p-Glycoprotein Transport Function at the Blood-Brain Barrier
2005
Efficacy of Fractionated Stereotactic Reirradiation in Recurrent Gliomas: Long-Term Results in 172 Patients Treated in a Single Institution
2005
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
2013 Standout
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma
2003
Diagnosis and Treatment of Recurrent High-Grade Astrocytoma
2006
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
2009
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
2007
Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors
2006
Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394
2003
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
2008 Standout
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
2008 Standout
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
2007
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
2008
MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
2009
Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data
2019
Development and validation of a predictive model for chemotherapy-associated thrombosis
2008 Standout
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
2007 Standout
Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
2008
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
2010 Standout
How effective is BCNU in recurrent glioblastoma in the modern era?
2004
Liver–brain interactions in inflammatory liver diseases: Implications for fatigue and mood disorders
2013
Works of Mario Ermani being referenced
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
2009
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas
2008
Temozolomide in Patients with Glioblastoma at Second Relapse after First Line Nitrosourea-Procarbazine Failure: A Phase II Study
2002
Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy
2004
Biochemical Markers of Endothelial Activation in Primary Hyperparathyroidism
2006
New Strategy Developments in Brain Tumor Therapy
2001
Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study
1997
Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme
1998
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
2006
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study
2001
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma
2009
First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia
2004
Change in MGMT methylation status between first and second surgery for recurrence: Clinical implications
2009
Is protracted low-dose temozolomide feasible in glioma patients?
2006
Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study
2006
Thalidomide neurotoxicity
2004
A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme
2002
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma
2016
MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
2008
Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
2004
Procarbazine and High-Dose Tamoxifen as a Second-Line Regimen in Recurrent High-Grade Gliomas: A Phase II Study
1999
Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With MGMT Promoter Methylation Status
2009
The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation
2000